These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19350293)

  • 21. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.
    Pfaller MA; Boyken LB; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Apr; 49(4):1274-9. PubMed ID: 21289155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.
    Rambach G; Oberhauser H; Speth C; Lass-Flörl C
    Med Mycol; 2011 Nov; 49(8):856-63. PubMed ID: 21619497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.
    Kondori N; Svensson E; Mattsby-Baltzer I
    Mycoses; 2011 Sep; 54(5):e318-22. PubMed ID: 20557462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
    Pfaller MA; Hata K; Jones RN; Messer SA; Moet GJ; Castanheira M
    Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
    Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.
    Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
    J Clin Microbiol; 2001 Nov; 39(11):3952-4. PubMed ID: 11682513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts.
    Cantón E; Pemán J; Espinel-Ingroff A; Martín-Mazuelos E; Carrillo-Muñoz A; Martínez JP
    J Antimicrob Chemother; 2008 Jan; 61(1):135-8. PubMed ID: 18033784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
    Lee SC; Lo HJ; Fung CP; Lee N; See LC
    J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.
    Bourgeois N; Dehandschoewercker L; Bertout S; Bousquet PJ; Rispail P; Lachaud L
    J Clin Microbiol; 2010 Jan; 48(1):154-61. PubMed ID: 19889902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
    Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
    J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
    Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
    Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).
    Saracli MA; Fothergill AW; Sutton DA; Wiederhold NP
    Med Mycol; 2015 Sep; 53(7):736-42. PubMed ID: 26162474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.